An acquisition last year by a Pacific Northwest biotech company has paid off, in the form of a successful registration-directed breast cancer study. The company – which is based in the suburb of ...
-Collaboration Combines Seattle Genetics’ Expertise in Cancer Targets and Antibody-Based Therapies with Unum’s Novel Antibody-Coupled T-cell Receptor (ACTR) Technology- -Companies to Focus on the ...
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2017. The company also highlighted ADCETRIS ...
The Food and Drug Administration is imposing a clinical hold on several of Seattle Genetics’ early-stage studies involving an experimental cancer drug following the deaths of four people, Reuters ...
Seattle Genetics (SGEN) shares soared 12.7% in the last trading session to close at $165.45. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...
Fintel reports that Capital International Investors has filed a 13G/A form with the SEC disclosing ownership of 18.06MM shares of Seattle Genetics, Inc. (SGEN). This represents 9.7% of the company. In ...
The field of human genetics and genomics research has seen spectacular progress and advances in human health and well-being that are nothing short of remarkable. In just a few years, we have been able ...
* Seattle Genetics announces global license agreement with immunomedics for sacituzumab govitecan (immu-132), a promising late-stage adc for solid tumors Sign up here. * Seattle Genetics Inc - planned ...
BOTHELL, Wash. (AP) - Biotechnology company Seattle Genetics Inc. said Thursday it will receive an $8 million fee from Pfizer Inc. for rights to use its cancer-fighting antibody-drug conjugate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results